Global Doxorubicin Market by Drug Formulation, Application, Distribution Channel and Geography - Forecast to 2023 - ResearchAndMarkets.com

October 11, 2018

DUBLIN--(BUSINESS WIRE)--Oct 11, 2018--The “Global Doxorubicin Market - Segmented by Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Application, Distribution Channel, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The global Doxorubicin market is expected to register a CAGR of 6.5% during the forecast period 2018 to 2023.

Developing countries are disproportionately affected by the growing numbers of cancers due to growing and aging populations. Hence the increasing number of cancer cases and the increasing need to treat them effectively and efficiently is going to help boost the market for doxorubicin in the forecast period.

Other factors driving the market growth are increasing application of doxorubicin and an increasing number of companies manufacturing doxorubicin.

Key Highlights

Increasing Prevalence of Cancer Worldwide Side Effects Associated With Doxorubicin May Hinder Growth North America is Expected to Dominate the Market

Major Market Developments

India, Hyderabad-based NATCO Pharma Ltd has announced that its co-development and marketing partner, Dr Reddy’s Laboratories Ltd, has filed for registration of doxorubicin hydrochloride liposome injection for intravenous use, in the European markets.

Companies Profiled

Cadila Pharmaceuticals Cipla Inc. Janssen Products Pfizer Inc. SRS Pharmaceuticals Pvt. Ltd. Sun Pharmaceutical Industries Ltd.

Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Market Dynamics

7. Market Segmentation

8. Company Profiles and Competitive Landscape

9. Future Outlook of the Market

For more information about this report visit https://www.researchandmarkets.com/research/krzc5j/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005423/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Lung Cancer Drugs ,Breast Cancer Drugs ,Ovarian Cancer Drugs ,Bladder Cancer Drugs ,Thyroid Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/11/2018 08:22 AM/DISC: 10/11/2018 08:21 AM


Update hourly